The estimated Net Worth of Stephen M Kanovsky is at least $750 Тысяча dollars as of 10 August 2024. Mr. Kanovsky owns over 11,336 units of Neogenomics stock worth over $588,628 and over the last 5 years he sold NEO stock worth over $0. In addition, he makes $161,868 as Independent Director at Neogenomics.
Sign up
Mr. Kanovsky NEO stock SEC Form 4 insiders trading
Stephen has made over 1 trades of the Neogenomics stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 11,336 units of NEO stock worth $184,890 on 10 August 2024.
The largest trade he's ever made was exercising 11,336 units of Neogenomics stock on 10 August 2024 worth over $184,890. On average, Stephen trades about 1,619 units every 0 days since 2019. As of 10 August 2024 he still owns at least 36,090 units of Neogenomics stock.
You can see the complete history of Mr. Kanovsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Kanovsky biography
Stephen Michael Kanovsky serves as Independent Director of the Company. Mr. Kanovsky, who has worked at General Electric since 2012, is General Counsel, Commercial of GE Healthcare, a business unit of General Electric that provides medical technologies and solutions to the global healthcare industry and supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life sciences. Mr. Kanovsky earned his bachelor’s degree from the University of Pennsylvania. He subsequently graduated from Temple University’s School of Pharmacy with a master’s degree in Pharmacology and Temple University’s School of Law with a juris doctorate degree. Mr. Kanovsky also holds a master’s degree in business administration from Saint Joseph’s University’s Haub School of Business.
What is the salary of Stephen Kanovsky?
As the Independent Director of Neogenomics, the total compensation of Stephen Kanovsky at Neogenomics is $161,868. There are 14 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
How old is Stephen Kanovsky?
Stephen Kanovsky is 57, he's been the Independent Director of Neogenomics since 2017. There are 12 older and 13 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
What's Stephen Kanovsky's mailing address?
Stephen's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Insiders trading at Neogenomics
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van и Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
What does Neogenomics do?
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
What does Neogenomics's logo look like?
Complete history of Mr. Kanovsky stock trades at Neogenomics
Neogenomics executives and stock owners
Neogenomics executives and other stock owners filed with the SEC include:
-
Douglas VanOort,
Chairman of the Board, Chief Executive Officer -
Robert Shovlin,
President - Clinical Services Division -
Lawrence Weiss,
Chief Medical Officer -
George Cardoza,
President - Pharma Services Division -
William Bonello,
President, Informatics and Director of Investor Relations -
Douglas M. Brown,
Chief Strategy & Corp. Devel. Officer -
Kathryn McKenzie,
Chief Financial Officer -
Steven Ross,
Chief Information Officer -
Steven Jones,
Director -
Alison Hannah,
Independent Director -
Lynn Tetrault,
Lead Independent Director -
Raymond Hipp,
Independent Director -
Bruce Crowther,
Independent Director -
Kevin Johnson,
Independent Director -
Stephen Kanovsky,
Independent Director -
Michael Kelly,
Independent Director -
Rachel Stahler,
Director -
Douglas Brown,
Chief Strategy and Corporate Development Officer -
Denise Pedulla,
General Counsel, Corporate Secretary -
Jennifer Balliet,
Vice President, Chief Culture Officer -
Stephanie Bywater,
Chief Compliance Officer -
Cynthia Dieter,
Chief Accounting Officer, Controller -
Dr. Steven G. Brodie FACMG, Ph.D.,
Sr. VP of Laboratory Operations -
George A. Cardoza,
Pres & COO of Lab Operations -
Marcus B. Silva J.D., M.B.A.,
Chief Marketing Officer -
Halley E. Gilbert Esq., J.D.,
Chief Legal Officer -
Charlie Eidson,
Director of Investor Relations and Corp. Devel. -
John Mooney,
Chief Technology Officer -
Cynthia J. Dieter,
Chief Accounting Officer & Controller -
Mark W. Mallon,
CEO & Director -
William J Robison,
Director -
Maher Albitar,
Chief Medical Officer -
Sharon Virag,
Chief Financial Officer -
David Sholehvar,
President, Clinical Services -
Neil Gunn,
Director -
Elizabeth Floegel,
Director -
Anthony P. Zook,
Director -
Christopher M Smith,
Chief Executive Officer -
Mark Alan Machulcz,
Vice President of Operations -
Michael T Dent,
Director -
Steven G. Brodie,
Chief Scientific Officer -
Steven Caspen Select Health...,
Executive VP of FinanceExecutive VP of Finance -
Robert H. Horel,
Vice President andGM PathLogic -
Robert P Gasparini,
Chief Science Officer -
Halley E Gilbert,
Chief Legal Officer -
Gina M Wallar,
President, Pharma Services -
Mark Mallon,
Chief Executive Officer -
Clive Morris,
President of Inivata -
Oort Douglas M Van,
Director -
David Daly,
Director -
Vishal Sikri,
President Advanced Diagnostics -
David Brian Perez,
Director -
Jeffrey Scott Sherman,
Chief Financial Officer -
Shashikant Kulkarni,
Chief Scientific Officer -
Alicia C Olivo,
General Counsel -
Melody Harris,
Chf Ops Off, Pres, Informatics -
Greg D Aunan,
Chief Accounting Officer -
Warren Stone,
Chief Commerical Officer